Evidence map›Paper›PMID 42237896›Full record

ArticleAngewandte Chemie (International ed. in English)2026

Chelator-Free Radiometal Labeling Inside Engineered Affibodies.

Lani J Davies, Upamali Somathilake, Santhanalaxmi Kumaresan, Frank Bruchertseifer, Alfred Morgenstern, Sarah Spreckelmeyer, Christoph Nitsche

Abstract read
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lani J DaviesResearch School of Chemistry, Australian National University, Canberra, Australia.
Upamali SomathilakeResearch School of Chemistry, Australian National University, Canberra, Australia.
Santhanalaxmi KumaresanResearch School of Chemistry, Australian National University, Canberra, Australia.
Frank BruchertseiferEuropean Commission, Joint Research Centre, Karlsruhe, Germany.
Alfred MorgensternEuropean Commission, Joint Research Centre, Karlsruhe, Germany.
Sarah SpreckelmeyerKlinik für Nuklearmedizin, Radiopharmazie, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Christoph NitscheResearch School of Chemistry, Australian National University, Canberra, Australia.ORCID 0000-0002-3704-2699

Funding

Australian Research Council DP230100079Australian Research Council FT220100010Future Fellowship FT220100010
6 · The paper itself

Abstract

Affibodies are remarkably stable three-helix bundle proteins that can be engineered to selectively bind target proteins. When combined with radioactive metals, they serve as imaging agents or cancer therapeutics, depending on the metal used. Traditionally, this involves bifunctional linkers that attach large chelators to the affibody via reactive groups. Here, we present an alternative approach that eliminates the need for such linkers by burying the metal within the core of the affibody, surrounded by its three helices. A simple engineered triple cysteine motif, with one cysteine in each helix, stably binds Bi(III), Pb(II), In(III), and Ga(III), which are commonly used in imaging and radiotherapy. Quantitative metal uptake is instantaneous at room temperature and physiological pH, and all metal-affibody complexes remain fully intact for one week at 4 °C. All retain their metal cargo when challenged with cellular concentrations of glutathione, while only the bismuth-affibody complex withstands a challenge with 100 equivalents of strong chelators, even over two weeks. We demonstrate that, a bismuth‑loaded affibody retains binding affinity to the HER2 receptor comparable to the wildtype affibody, while selectively binding and retaining

Indexed as

Chelating AgentsProtein EngineeringRecombinant Fusion ProteinsBismuthHumansLeadBismuthChelating AgentsLeadRecombinant Fusion Proteinsaffibodyalpha particlebismuthhelix bundleradiolabel

Identifiers

PMID42237896
PMCPMC13382918

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.